首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1958587

穿戴式注射器市场（第8版）：依装置类型、自动化程度、用途、治疗领域和地区划分 - 趋势及至2035年的预测

Wearable Injectors Market (8th Edition): Distribution by Type of Device, Degree of Automation, Usability, Therapeutic Area, and Geographical Regions - Trends and Forecast Till 2035

出版日期: 2026年02月17日 | 出版商:

Roots Analysis | 英文 702 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

穿戴式注射器市场 - 概述

全球穿戴式注射器市场预计将从目前的68亿美元成长到2035年的130亿美元，预测期内（～2035年）的年复合成长率（CAGR）为 7.4%。

穿戴式注射器市场 - 成长与趋势

自体免疫疾病、心臟病和癌症的盛行率不断上升，加上人口老化加剧，持续给医疗保健系统带来压力。为了应对这项挑战，製药公司开发以患者为中心的解决方案，透过先进的药物输送技术来提高治疗依从性和疗效。穿戴式注射器，例如佩戴在身上的贴片泵，可以透过持续基础输注、推注或持续输注的方式输送大剂量生物製剂，简化给药流程并提高患者依从性。整合式安全功能可最大限度地减少针刺伤，同时确保居家使用的舒适性和可靠性。为了说明这一趋势，BD 近期宣布启动首个由製药公司赞助的临床试验，该试验使用 BD Libertas 可穿戴式注射器进行复杂生物製剂的皮下注射，凸显了人们对这些高容量、便捷易用的居家护理系统的信心日益增强。这些进步使得穿戴式装置成为居家医疗保健环境中皮下给药的首选方案。此外，穿戴式注射器的广泛应用促使製药和医疗器材製造商在其产品线中融入先进功能，包括人工智慧演算法、具备智慧健康监测、提醒和用药确认视觉或听觉通知功能的行动应用程式。该领域的持续进步预计将显着提高这些穿戴式注射器的使用率，并在不久的将来进一步推动市场扩张。

成长驱动因素：市场扩张的策略驱动因素

穿戴式注射器市场的驱动因素包括糖尿病、肿瘤和自体免疫疾病等慢性病盛行率的上升。这些因素推动了对便利的生物製剂皮下注射和高剂量疗法的需求。此外，家庭医疗保健的兴起使得患者能够自我用药，减少了就医次数，提高了患者的自主性和依从性，进一步推动了市场成长。小型化、用于即时监测的无线连接以及与数位健康平台的整合等技术进步进一步加速市场普及。

市场挑战：发展的主要障碍

阻碍穿戴式注射器广泛应用的主要挑战包括不断上涨的研发和生产成本，尤其是在偿付体系薄弱的新兴市场。此外，严格的监管要求会延缓这些设备的审批，并增加製造商的合规负担。病患相关的障碍，例如缺乏装置使用训练以及对安全性和舒适性的担忧，加上现有给药方式的竞争，也阻碍了穿戴式注射器的广泛应用。

穿戴式注射器市场 - 主要洞察

本报告深入分析了穿戴式注射器市场的现状，并指出了该行业的潜在成长机会。主要发现包括：

在目前的市场格局中，有超过 50 种不同类型的可穿戴胰岛素注射器。开发这些注射器的公司中，中型企业比例相对较高（约 40%）。

目前，约 65%的可穿戴胰岛素注射器已实现商业化，其中大部分针对第1 型糖尿病患者，可为需要频繁给药的患者提供强化基础胰岛素和餐前胰岛素治疗。
在目前的市场环境下，全球有多家公司开发用于非胰岛素药物给药的可穿戴注射器，其中大多数（64%）总部位于欧洲。
使用储存非胰岛素药物的药筒的可穿戴注射器约占市场占有率的70%。此外，约 85%的装置具备蓝牙连接功能，可实现进阶监测和资料整合。
目前全球已有近20种药物-器械组合可用于输送非胰岛素类药物。其中超过55%的器械由大型公司利用其先进的製造能力开发。
用于输送非胰岛素类药物的药物-器械组合中，60%已商业化。这些器械组合在神经系统疾病和肿瘤的治疗中应用尤为广泛。
在穿戴式注射器领域，已发表的专利中约有70%为专利申请，其中大部分专利（约75%）在北美公布。
穿戴式注射器具有诸多优势，例如能够实现药物的自我给药和降低医疗成本，因此受到众多投资者的支持，自2020年以来已累计投资超过 165亿美元。

目前已註册多项临床试验，目的是评估各种穿戴式注射器的安全性和有效性。其中大部分研究已在美国各地的医疗机构进行。
由于慢性病盛行率的上升以及以家庭为基础、以患者为中心的护理模式的转变，预计未来几年可穿戴注射器市场将实现强劲成长。
由于贴片式胰岛素帮浦设计隐蔽纤薄、患者舒适度高且易于自我注射，预计将占据最大的市场占有率。
目前，北美地区穿戴式胰岛素注射器市场占据主导地位，这得益于其先进的医疗基础设施和整合式 CGM 相容帮浦技术的广泛应用。

受慢性病患病率上升和该地区有利的医保偿付环境的推动，预计今年北美可穿戴式注射器市场将占据最大的市场占有率。
受以患者为中心的大容量注射器需求不断成长的推动，预计美国可穿戴注射器市场在预测期内将以更高的年复合成长率成长。
鑑于强大的药物研发管线和对家庭医疗保健日益成长的关注，预计未来几年可穿戴注射器市场将实现显着成长。

穿戴式注射器市场

市场规模和机会分析基于以下参数进行细分：

依设备划分的市场

贴片泵
输液泵

依自动化程度划分的市场

自动/智慧型泵
手动泵

依用途划分的市场

抛弃式
可重复使用（抛弃式零件）

依治疗领域划分的市场

肿瘤学
心血管疾病
自体免疫疾病
神经系统疾病
其他

依地区划分的市场

北美
美国
加拿大
墨西哥
欧洲
法国
德国
英国
义大利
西班牙
其他欧洲国家
亚洲
中国
印度
日本
巴基斯坦
其他亚洲国家
中东和北非
埃及
以色列
沙乌地阿拉伯
拉丁美洲
阿根廷
巴西

穿戴式注射器市场 - 主要细分市场

输液帮浦细分市场占据最大的市场占有率

穿戴式胰岛素注射器市场整体分为各种设备类型，例如贴片帮浦和输液帮浦。根据预测，输液帮浦类别约占穿戴式注射器现有市场占有率的95%。这主要归功于其在药物给药方面无与伦比的精准性和适应性等优势。此外，由于居家使用和自我给药的便利性不断提高，贴片帮浦细分市场未来预计将实现更高的年复合成长率。其隐藏的设计使其成为糖尿病和癌症等疾病持续治疗的理想选择，随着疾病发生率的上升，预计其应用将迅速普及。

北美：占据市场主导地位，市场占有率最大

北美在穿戴式注射器市场占据最大的市场占有率（约占 70%）。先进的医疗保健体系、慢性病高发生率以及医疗保健支出不断增加等因素是推动该地区市场成长的关键因素。

肿瘤领域引领非胰岛素穿戴式注射器市场。

整个市场根据治疗领域细分为多个子领域，包括癌症相关疾病、心臟病、神经系统疾病、自体免疫疾病以及其他各种疾病。根据对非胰岛素药物穿戴式注射器的市场分析，肿瘤领域是推动市场成长的主要因素，这主要归因于癌症的高发生率以及对复杂生物製剂和化疗药物精准给药的需求。预计神经科领域在整个预测期内将以更高的年复合成长率成长。

穿戴式注射器市场的主要参与者

Becton Dickinson（BD）
Enable Injections
Insulet
Medtronic
Tandem Diabetes Care
West Pharmaceutical Services
Ypsomed

穿戴式注射器市场 - 研究范围

市场规模和机会分析：本报告对穿戴式注射器市场进行了详细分析，重点关注以下关键市场细分：[A] 设备类型，[B] 自动化程度，[C] 用途，[D] 治疗领域，以及 [E] 地理区域。
非胰岛素药物穿戴式注射器市场概况：非胰岛素药物穿戴式注射器穿戴式注射器市场概况包括以下资讯：[A] 设备类型，[B] 研发状态，[C] 给药方式，[D] 易用性，[E] 药物储库容量，[F] 药物分子类型，[G] 给药方式，[H] 注射方式，[I] 治疗领域，[J] 药物容器，[K]年份药物灌装公司规模，[K] 总部所在地，以及 [L] 主要厂商。
非胰岛素药物-器械组合市场概况：除了对非胰岛素药物-器械组合市场中可穿戴注射器的整体市场概况进行详细概述外，此市场概况还包括以下资讯：[A] 器械类型，[B] 研发状态，[C] 给药方式，[D] 用途，[E] 药物储库容量，[F] 药物分子类型，[G] 药物类型，[E] 药物库容量，[F] 药物分子类型，[G] [I] 领域，[F]，药物容器类型，[K] 药物填充方式，[H] 主要参与者，[I] 成立年份，[J] 公司规模，[K] 总部所在地，以及 [L] 主要参与者。
穿戴式胰岛素注射器市场概览：本报告详细概述了可穿戴胰岛素注射器市场的整体市场格局，包括以下资讯：[A] 设备类型，[B] 研发现状，[C] 给药方式，[D] 用途，[E] 药物储库容量，药物分子类型，[F] 剂量类型，[G] 药物剂量，[HI] 容器类型，[HI] 治疗领域，[KJ] 药物剂量，[HI] 治疗容器药物填充方法，[H] 主要参与者，[I] 成立年份，[J] 公司规模，[K] 总部所在地，以及 [L] 主要参与者。
公司简介：本报告详细介绍了北美、欧洲和亚太地区主要可穿戴注射器製造商的概况，包括：[A] 成立年份，[B] 总部所在地，[C] 产品组合，[D] 近期发展，以及 [E] 未来展望。
专利分析：基于多个相关参数，对过去十年中与可穿戴注射器相关的已提交和已授权专利进行详细分析，这些参数包括：[A] 专利类型，[B] 专利公开年份，[C] 管辖地，[D] CPC 分类号，[E] 组织类型，[F] 新兴关注领域，[G] 最活跃的参与者，[F] 专利分析
有前景的候选药物：概述已上市药物/疗法和在研药物，这些药物/疗法和在研药物可能在不久的将来与可穿戴注射器联合开发。基于详细分析，识别出潜在的候选药物（已上市药物和临床阶段药物），并考虑了以下多个参数：[A] 药物分子类型，[B] 研发阶段，[C] 适应症，[D] 给药频率，[E] 疗法类型，[F] 给药方法，以及 [G] 给药途径。
临床试验分析：基于以下相关参数，对已完成、进行和计划中的可穿戴注射器相关临床试验进行详细分析：[A] 研究招募状态，[B] 研究註册年份，[C] 研究阶段，[D] 研究设计，[E] 申办方/合作方类型，[F] 主要参与者（基于註册试验数量），[G] 申办领域/合作方类型，[F] 主要参与者（基于註册试验数量），[G] 领域治疗领域，[I] 地理范围，[I] 地理范围，[F] 领域，[I] 地理范围，[I] 领域。 [G] 重点领域，[H] 治疗领域，[I] 地区。
资金与投资分析：基于以下相关参数，对该领域的资金和投资交易进行详细分析：[A] 资金年份，[B] 资金类型，[C] 投资金额，[D] 地区，[E] 主要参与者。
SWOT 分析：对连网/智慧型药物输送设备开发过程中包括的各个阶段（研发、产品製造/组装、产品分销、行销/销售、上市后监测）进行详细的价值链分析，并提供各阶段的成本资讯。
监管环境和偿付政策：考虑北美（美国、加拿大、墨西哥）、欧洲（英国、法国、德国、义大利、西班牙及其他欧洲国家）、亚太地区以及世界其他地区（澳洲、巴西、中国、印度、以色列、日本、纽西兰、新加坡、南非、韩国、台湾和泰国）的医疗器材审批监管指南。
市场影响分析：详细分析可能影响穿戴式注射器市场成长的因素。这也包括识别和分析关键驱动因素、潜在限制因素、新兴机会和现有挑战。

章节概述
非胰岛素药物穿戴式注射器开发商
- CCBio
- E3D Elcam Drug Delivery Devices
- Enable Injections
- Gerresheime注射
- Sonceboz
- Weibel CDS（Acquired by SHL Medical）
- West Pharmaceuticals
用于胰岛素药物的可穿戴注射器开发商
- CeQu注射
- Debiotech
- Eli Lilly
- Insulet
- Medtronic
- Medtrum Technologies
- PharmaSens
- Roche
- SOOIL Development

第12章药物-器械组合：器械简介

章节概述
Neulasta®（pegfilgrastim）OnPro™Kit
D-mine®泵
Lasix®ONYU
The LUTREPULSE®系统
ND0612L新一代贴片泵
Unnamed（Phillips Medisize开发）
FUROSCIX®
SMT-201 泵
SMT-301 泵
ULTOMRIS®智慧剂量注射器（ravulizumab-cwvz）
EMPAVELI®Injector
SKYRIZI®On Body Injector（risankizumab）
VYALEV™泵（foscarbidopa and foslevodopa）
UDENYCA®体外注射器
ONAPGO™
Remunity®泵
G-Lasta®BodyPod
Sarclisa（isatuximab）体外注射器

第13章合作与伙伴关係

第14章重点收购目标

第15章专利分析

第16章穿戴式注射器：有前景的候选药物

章节概述
已上市药物
临床阶段药物

第17章临床试验分析

章节概述
研究范围与方法
穿戴式注射器：临床试验分析

第18章资金与投资分析

章节概述
融资类型
穿戴式注射器：融资与投资分析

第19章 SWOT分析

第20章案例研究：合约製造组织在医疗器材开发供应链中的作用

第21章医疗器材监管与偿付现况

章节概述
医疗器材监管和偿付通用指南
北美监理与偿付现状
欧洲监管和偿付现状
亚太及其他地区监管及偿付现状

第22章市场影响分析：驱动因素、限制因素、机会与挑战

章节概述
市场驱动因素
市场限制因素
市场机会
市场挑战
结论

第23章非胰岛素药物穿戴式注射器

第24章非胰岛素药物穿戴式注射器（依装置类型划分）

第25章非胰岛素药物穿戴式注射器市场（依用途划分）

第26章非胰岛素药物穿戴式注射器市场（依治疗领域划分）

第27章非胰岛素药物穿戴式注射器市场（依地区划分）

第28章胰岛素药物穿戴式注射器市场

第29章胰岛素药物穿戴式注射器市场（依装置类型划分）

第30章胰岛素药物穿戴式注射器市场（依自动化程度划分）

第31章胰岛素药物穿戴式注射器市场（依地区划分）

第32章结论

第33章高层洞察

第34章附录1：表格资料

第35章附录2：公司与组织列表

简介目录图表

Product Code: RA100452

Wearable Injectors Market: Overview

As per Roots Analysis, the global wearable injectors market is estimated to grow from USD 6.8 billion in the current year to USD 13.0 billion by 2035, at a CAGR of 7.4% during the forecast period, till 2035.

Wearable Injectors Market: Growth and Trends

The rise in autoimmune diseases, heart conditions, and cancer continues to put pressure on healthcare systems as the population grows and ages. In response, pharmaceutical companies are developing patient-focused solutions to enhance treatment adherence and outcomes through advanced drug delivery technologies. Wearable injectors, such as on-body patch pumps, provide sustained basal, bolus, or continuous doses of large-volume biologics, making administration easier and improving adherence. Their integrated safety features minimize needlestick injuries, while ensuring comfort and confidence when used at home. Illustrating this trend, BD recently announced the launch of the first clinical trial sponsored by a pharmaceutical company for a combination product using the BD Libertas wearable injector for the subcutaneous delivery of complex biologics. This highlights the increasing trust in these large-volume, patient-friendly systems for at-home care.

Due to this development, wearable devices have emerged as the favored option for administering drugs subcutaneously in home-care environments. In addition, the rise in popularity of on-body injectors has led pharmaceutical companies and medical device manufacturers to incorporate advanced features into their product lines. These features include artificial intelligence algorithms, mobile applications with intelligent health monitoring, reminders, and visual or audible notifications confirming drug delivery. With constant advancements occurring in this sector, it is anticipated that the usage of such on-body injectors will rise substantially, fueling market expansion in the foreseeable future.

Growth Drivers: Strategic Enablers of Market Expansion

The market drivers in the wearable injector's domain include rising prevalence of chronic diseases like diabetes, oncology, and autoimmune disorders, which fuels the demand for convenient subcutaneous delivery of biologics and high-volume therapies. In addition, the market is fueled by the growing preference for home healthcare enables self-administration, reducing clinic visits and enhancing patient autonomy and adherence. Technological advancements, including miniaturization, wireless connectivity for real-time monitoring, and integration with digital health platforms, further accelerate the market adoption.

Market Challenges: Critical Barriers Impeding Progress

Key challenges hindering the adoption of wearable injectors include rising development and production costs especially in emerging markets with weak reimbursement infrastructure. Further, stringent regulatory requirements delay approvals of these devices and raise compliance burdens for manufacturers. Patient-related barriers, such as lack of training on device use and concerns over safety or comfort, hinder widespread adoption alongside competition from established delivery methods.

Wearable Injectors Market: Key Insights

The report delves into the current state of the wearable injectors market and identifies potential growth opportunities within industry. Some key findings from the report include:

The current market landscape features more than 50 wearable injectors for insulin drugs; a relatively higher proportion (~40%) of the companies developing such injectors are mid-sized players.

About 65% of wearable injectors for insulin drugs are commercialized; of these, majority of devices are targeting Type I diabetes to enable intensive basal-bolus insulin regimens for patients requiring frequent dosing.
The current market landscape features the presence of several companies developing wearable injectors for the delivery of non-insulin drugs worldwide; majority (64%) of these firms are headquartered in Europe.
Around 70% of the wearable injectors utilize cartridges for storing non-insulin drugs; further, about 85% of the devices offer Bluetooth connectivity, enabling enhanced monitoring and data integration capabilities.
Close to 20 drug-device combinations are available for delivering non-insulin drugs globally; over 55% of these devices have been developed by relatively larger players utilizing their advanced manufacturing capabilities.
60% of drug-device combinations for delivering non-insulin drugs are commercialized; notably, such device combinations are more popular for neurological and oncological disorders.
Around 70% of the patents published in the wearable injectors domain are patent applications; notably, majority (~75%) of the patents have been published in North America.
Given various benefits of wearable injectors in enabling self-administration of drugs and reducing healthcare costs, several investors have extended financial support; over USD 16.5 billion has been invested since 2020.

Several clinical trials have been registered till date to evaluate the safety and efficacy of various wearable injectors; majority of these studies have been conducted across various sites in the US.
Driven by the rising prevalence of chronic diseases and the shift towards home-based, patient-centric care models, the wearable injectors market is anticipated to witness robust growth over the coming years.
Patch pumps are expected to capture the largest market share due to their discreet low-profile design, superior patient comfort, and simpler self-administration.
Currently, the majority share in the wearable injectors market for insulin is captured by North America owing to its advanced healthcare infrastructure and widespread adoption of integrated CGM-enabled pump technologies.

The wearable injectors market in North America is expected to capture maximum share in current year, owing to the rising prevalence of chronic diseases and a favorable reimbursement landscape in this region.
The wearable injectors market in the US is poised to grow at a higher CAGR over the forecast period, driven by the rising demand for patient-centric large-volume injectors.
Given the robust drug development pipeline and rising focus on home-based care, the wearable injectors market is poised for substantial growth in the coming years.

Wearable Injectors Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Market by Type of Device

Patch Pumps
Infusion Pumps

Market by Degree of Automation

Automated / Smart Pump
Manual Pumps

Market by Usability

Disposable
Reusable (Disposable Components)

Market by Therapeutic Area

Oncological Disorders
Cardiovascular Disorders
Autoimmune Disorders
Neurological Disorders
Other Disorders

Market by Geographical Regions

North America
US
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia
China
India
Japan
Pakistan
Rest of Asia
Middle East and North Africa
Egypt
Israel
Saudi Arabia
Latin America
Argentina
Brazil

Wearable Injectors Market: Key Segments

Infusion Pumps Segment Account for the Largest Market Share

The overall market for wearable insulin injectors is divided into various device types, including patch pumps and infusion pumps. According to our projections, the infusion pumps category represents around 95% of the existing market share for wearable injectors. This is due to its advantages, including their unparalleled accuracy and adaptability in administering drugs. Further, the patch pumps segment is expected to experience a higher CAGR in the future, due to the fact that they provide enhanced convenience for home use and self-administration. Their discreet design is ideal for ongoing treatments (such as diabetes and cancer), facilitating swift adoption as disease rates increase.

North America: Dominating the Market by Securing Highest Share

North America accounts for largest wearable injectors market size (with nearly 70% of the market share). Several factors, such as advanced healthcare system, high prevalence of chronic diseases and increased investment in healthcare spending are some of the prominent factors driving the market growth in this region.

Oncological Disorders Segment Dominates the Non-Insulin Wearable Injectors Market

The overall market is divided into sub-segments according to therapeutic areas, which include cancer-related disorders, heart disorders, neurological issues, autoimmune conditions, and various other disorders. Based on our analysis of the non-insulin wearable injector market, the oncological disorders segment leads the market, owing to the significant incidence of cancer and the accuracy of these devices for administering complex biologics and chemotherapy. The segment for neurological disorders is expected to grow at a greater CAGR throughout the forecast period.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:

Chief Executive Officer, Small Company, US
Chief Executive Officer, Mid Sized Company, US
Chief Executive Officer, Small Company, Denmark
Former President and Chief Executive Officer, Mid Sized Company, US
Vice President and Chief Scientist, Large Company, Israel
Former Vice President and General Manager, Biologics, Very Large Company, US
Anonymous, Large Company, Switzerland
Engineering Project Manager / Senior System Engineer, Small Company, Switzerland
Vice President, Marketing and Alliance Management, Mid Sized Company, US

Example Players in Wearable Injectors Market

Becton Dickinson (BD)
Enable Injections
Insulet
Medtronic
Tandem Diabetes Care
West Pharmaceutical Services
Ypsomed

Wearable Injectors Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the wearable injectors market, focusing on key market segments, including [A] type of device [B] degree of automation, [C] usability, [D] therapeutic area, and [E] geographical regions.
Wearable Injectors for Non-Insulin Drugs Market Landscape: A detailed overview of the overall market landscape of wearable injectors for non-insulin drugs market landscape, along with information on several relevant parameters, such as [A] type of device, [B] status of development, [C] type of drug delivery, [D] usability, [E] drug reservoir volume, type of drug molecule, [F] type of dose, [G] dose of drug, [H] mode of injection, [I] therapeutic area, [J] type of drug container, [K] mode of drug filling, [H] most active players, [I] year of establishment, [J] company size, [K] location of headquarters and [L] leading players.
Drug Device Combinations for Non-Insulin Drugs Market Landscape: A detailed overview of the overall market landscape of wearable injectors for drug device combinations for non-insulin drugs market landscape, along with information on several relevant parameters, such as [A] type of device, [B] status of development, [C] type of drug delivery, [D] usability, [E] drug reservoir volume, type of drug molecule, [F] type of dose, [G] dose of drug, [H] mode of injection, [I] therapeutic area, [J] type of drug container, [K] mode of drug filling, [H] most active players, [I] year of establishment, [J] company size, [K] location of headquarters and [L] leading players.
Wearable Injectors for Insulin Market Landscape: A detailed overview of the overall market landscape of wearable injectors for insulin drugs market landscape, along with information on several relevant parameters, such as [A] type of device, [B] status of development, [C] type of drug delivery, [D] usability, [E] drug reservoir volume, type of drug molecule, [F] type of dose, [G] dose of drug, [H] mode of injection, [I] therapeutic area, [J] type of drug container, [K] mode of drug filling, [H] most active players, [I] year of establishment, [J] company size, [K] location of headquarters and [L] leading players.
Company Profiles: In-depth profiles of leading players manufacturing wearable injectors in North America, Europe and Asia-Pacific based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
Patent Analysis: An in-depth analysis of patents that have been filed / granted related to wearable injectors over the last decade across several relevant parameters, such as [A] type of patent, [B] patent publication year, [C] jurisdiction, [D] CPC symbol, [E] type of organization, [F] emerging focus area, [G] most active players, [H] patent benchmarking analysis and [I] insightful patent valuation analysis.
Likely Drug Candidates: An overview of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates (marketed drugs and clinical-stage drugs), taking into consideration multiple parameters, such as [A] type of drug molecule, [B] phase of development, [C] indication, [D] dosing frequency, [E] type of therapy, [F] method of administration and [G] route of administration.
Clinical Trial Analysis: A detailed analysis of completed, ongoing and planned clinical trials related to wearable injectors based on several relevant parameters, such as [A] trial recruitment status, [B] trial registration year, [C] trial phase, [D] study design, [E] type of sponsor / collaborator, [F] leading players (based on the number of registered trials), [G] key focus area, [H] therapeutic area, and [I] geography.
Funding and Investment Analysis: An analysis of funding and investment signed in the domain based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount invested, [D] geography, [E] and most active players.
SWOT Analysis: An in-depth value chain analysis featuring a discussion on various steps involved in the development of connected / smart drug delivery devices, including research and development (R&D), product manufacturing and assembly, product distribution, marketing and sales, and post-market surveillance, along with the information on cost requirements across each of the aforementioned stages.
Regulatory and Reimbursement Landscape: A discussion on the various guidelines established by regulatory bodies for medical device approvals across North America (US, Canada and Mexico), Europe (UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand).
Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of wearable injectors market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

Key Questions Answered in this Report

Which are the leading companies in wearable injectors market?
Which region dominates the wearable injectors market?
What are the key trends observed in the wearable injectors market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by wearable injectors developers?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

Complementary PPT Insights Pack
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Introduction to Drug Delivery Devices
6.3. Conventional Parenteral Drug Delivery Devices
- 6.3.1. Needlestick Injuries
- 6.3.2. Incidence and Cost Burden
- 6.3.3. Prevention of Needlestick Injuries
- 6.3.4. Government Legislations for the Prevention of Needlestick Injuries
6.4. Emergence of Self-Administration Devices
- 6.4.1. Key Driving Factors
  - 6.4.1.1. Rising Burden of Chronic Diseases
  - 6.4.1.2. Healthcare Cost Savings
  - 6.4.1.3. Need for Immediate Treatment in Emergency Situations
  - 6.4.1.4. Growing Injectable Drugs Market
  - 6.4.1.5. Need for Improving Medication Adherence
6.5. Available Self-Injection Devices
- 6.5.1. Prefilled Syringes
- 6.5.2. Pen-Injectors
- 6.5.3. Needle-Free Injectors
- 6.5.4. Autoinjectors
- 6.5.5. Wearable Injectors
6.6. Regulatory Considerations
- 6.6.1. Medical Devices
- 6.6.2. Drug Device Combination Products
6.7. Future Perspectives

7. WEARABLE INJECTORS FOR NON-INSULIN DRUGS: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Wearable Injectors for Non-Insulin Drugs: Overall Market Landscape
- 7.2.1. Analysis by Type of Device
- 7.2.2. Analysis by Status of Development
- 7.2.3. Analysis by Type of Drug Delivery
- 7.2.4. Analysis by Usability
- 7.2.5. Analysis by Drug Reservoir Volume
- 7.2.6. Analysis by Type of Drug Molecule
- 7.2.7. Analysis by Type of Dose
- 7.2.8. Analysis by Dose of Drug
- 7.2.9. Analysis by Mode of Injection
- 7.2.10. Analysis by Therapeutic Area
- 7.2.11. Analysis by Type of Drug Container
- 7.2.12. Analysis by Mode of Drug Filling
7.3. Wearable Injectors for Non-Insulin Drugs: Developer Landscape
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters
- 7.3.4. Leading Players: Analysis by Number of Wearable Injectors Developed for Non-Insulin

8. DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Drug Device Combinations for Non-Insulin Drugs: Overall Market Landscape
- 8.2.1. Analysis by Type of Device
- 8.2.2. Analysis by Status of Development
- 8.2.3. Analysis by Type of Drug Delivery
- 8.2.4. Analysis by Usability
- 8.2.5. Analysis by Drug Reservoir Volume
- 8.2.6. Analysis by Type of Drug Molecule
- 8.2.7. Analysis by Type of Dose
- 8.2.8. Analysis by Dose of Drug
- 8.2.9. Analysis by Mode of Injection
- 8.2.10. Analysis by Therapeutic Area
- 8.2.11. Analysis by Type of Drug Container
- 8.2.12. Analysis by Mode of Drug Filling
8.3 Drug Device Combinations for Non-Insulin Drugs: Developer Landscape
- 8.3.1. Analysis by Year of Establishment
- 8.3.2. Analysis by Company Size
- 8.3.3. Analysis by Location of Headquarters
- 8.3.4. Device Developers: Distribution by Number of Drug Device Combination Developed

9. WEARABLE INJECTORS FOR INSULIN: MARKET LANDSCAPE

9.1. Chapter Overview
9.2. Wearable Injectors for Insulin: Overall Market Landscape
- 9.2.1. Analysis by Type of Device
- 9.2.2. Analysis by Status of Development
- 9.2.3. Analysis by Type of Insulin Delivery
- 9.2.4. Analysis by Type of Automated Insulin Delivery
- 9.2.5. Analysis by Type of Connectivity Feature
- 9.2.6. Analysis by Type of Feedback Mechanism
- 9.2.7. Analysis by Waterproofing Capability
- 9.2.8. Analysis by Usability
- 9.2.9. Analysis by Period of Use
- 9.2.10. Analysis by Type of Advanced Feature
- 9.2.11. Analysis by Type of Drug Container
- 9.2.12. Analysis by Mode of Drug Filling
- 9.2.13. Analysis by Type of Dose
- 9.2.14. Analysis by Type of Diabetes
- 9.2.15. Analysis by Availability of Connectivity Feature
9.3. Wearable Injectors for Insulin: Developer Landscape
- 9.3.1. Analysis by Year of Establishment
- 9.3.2. Analysis by Company Size
- 9.3.3. Analysis by Location of Headquarters
- 9.3.4. Leading Players: Analysis by Number of Wearable Injectors Developed for Insulin

10. PRODUCT COMPETITIVENESS ANALYSIS

10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Methodology
10.4. Product Competitiveness Analysis
- 10.4.1. Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
- 10.4.2. Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
- 10.4.3. Product Competitiveness Analysis: Wearable Injectors for Insulin

11. WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES

11.1. Chapter Overview
11.2. Key Players Developing Wearable Injectors for Non-Insulin
- 11.2.1. CCBio
  - 11.2.1.1. Company Overview
  - 11.2.1.2. Product Portfolio
  - 11.2.1.3. Recent Developments and Future Outlook
- 11.2.2. E3D Elcam Drug Delivery Devices
- 11.2.3. Enable Injections
- 11.2.4. Gerresheimer
- 11.2.5. Sonceboz
- 11.2.6. Weibel CDS (Acquired by SHL Medical)
- 11.2.7. West Pharmaceuticals
11.3. Key Players Developing Wearable Injectors for Insulin
- 11.3.1. CeQur
- 11.3.2. Debiotech
- 11.3.3. Eli Lilly
- 11.3.4. Insulet
- 11.3.5. Medtronic
- 11.3.6. Medtrum Technologies
- 11.3.7. PharmaSens
- 11.3.8. Roche
- 11.3.9. SOOIL Development

12. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES

12.1. Chapter Overview
12.2. Neulasta(R) (pegfilgrastim) OnPro(TM) Kit
12.3. D-mine(R) Pump
12.4. Lasix(R) ONYU
12.5. The LUTREPULSE(R) System
12.6. ND0612L Next generation patch pump
12.7. Unnamed (Developed by Phillips Medisize)
12.8. FUROSCIX(R)
12.9. SMT-201 Pump
12.10. SMT-301 Pump
12.11. ULTOMRIS(R) Smartdose Injector (ravulizumab-cwvz)
12.12. EMPAVELI(R) Injector
12.13. SKYRIZI(R) On Body Injector (risankizumab)
12.14. VYALEV(TM) Pump (foscarbidopa and foslevodopa)
12.15. UDENYCA(R) on-body injector
12.16. ONAPGO(TM)
12.17. Remunity(R) Pump
12.18. G-Lasta(R) BodyPod
12.19. Sarclisa (isatuximab) On-Body Injector

13. PARTNERSHIPS AND COLLABORATIONS

13.1. Chapter Overview
13.2. Partnership Models
13.3. Wearable Injectors: Partnerships and Collaborations
- 13.3.1. Analysis by Year of Partnership
- 13.3.2. Analysis by Type of Partnership
- 13.3.3. Analysis by Year and Type of Partnership
- 13.3.4. Analysis by Type of Partner
- 13.3.5. Analysis by Type of Device
- 13.3.6. Most Active Players: Analysis by Number of Partnerships
- 13.3.7. Analysis by Geography
  - 13.3.7.1. Local and International Agreements
  - 13.3.7.2. Intercontinental and Intracontinental Agreements

14. KEY ACQUISITION TARGETS

14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Scoring Criteria and Key Assumptions
14.4. Potential Acquisition Targets: Non-Insulin Drug Delivery Device Developers
14.5. Potential Acquisition Targets: Insulin Drug Delivery Device Developers
14.6. Concluding Remarks

15. PATENT ANALYSIS

15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Wearable Injectors: Patent Analysis
- 15.3.1. Analysis by Type of Patent
- 15.3.2. Analysis by Patent Publication Year
- 15.3.3. Analysis by Patent Application Year
- 15.3.4. Analysis of Granted Patents and Patent Applications by Publication Year
- 15.3.5. Analysis by Jurisdiction
- 15.3.6. Analysis by Type of Applicant
- 15.3.7. Analysis by Patent Age
- 15.3.8. Analysis by CPC Symbol
- 15.3.9. Most Active Players: Analysis by Number of Patents
15.4. Wearable Injectors: Patent Benchmarking Analysis
- 15.4.1. Analysis by Patent Characteristics
15.5. Patent Valuation
15.6. Leading Patents by Number of Citations

16. WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

16.1. Chapter Overview
16.2. Marketed Drugs
- 16.2.1. Most Likely Candidates for Delivery via Wearable Injectors
- 16.2.2. Likely Candidates for Delivery via Wearable Injectors
- 16.2.3. Less Likely Candidates for Delivery via Wearable Injectors
- 16.2.4. Least Likely Candidates for Delivery via Wearable Injectors
16.3. Clinical Stage Drugs
- 16.3.1. Most Likely Candidates for Delivery via Wearable Injectors
- 16.3.2. Likely Candidates for Delivery via Wearable Injectors
- 16.3.3. Less Likely Candidates for Delivery via Wearable Injectors
- 16.3.4. Least Likely Candidates for Delivery via Wearable Injectors

17. CLINICAL TRIAL ANALYSIS

17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Wearable Injectors: Clinical Trial Analysis
- 17.3.1. Analysis by Trial Recruitment Status
- 17.3.2. Analysis by Trial Registration Year
- 17.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
- 17.3.4. Analysis by Trial Phase
- 17.3.5. Analysis of Enrolled Patient Population by Trial Phase
- 17.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
- 17.3.7. Analysis by Study Design
- 17.3.8. Analysis by Type of Sponsor / Collaborator
- 17.3.9. Analysis by Therapeutic Area
- 17.3.10. Most Active Players: Analysis by Number of Registered Trials
- 17.3.11. Most Popular Wearable Injectors: Analysis by Number of Registered Trials
- 17.3.12. Analysis by Geography
  - 17.3.12.1. Analysis by Trial Recruitment Status and Geography
  - 17.3.12.2. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography

18. FUNDING AND INVESTMENT ANALYSIS

18.1. Chapter Overview
18.2. Types of Funding
18.3. Wearable Injectors: Funding and Investment Analysis
- 18.3.1. Analysis by Year of Funding
- 18.3.2. Analysis of Amount Invested by Year
- 18.3.3. Analysis by Type of Funding
- 18.3.4. Analysis by Type of Device
- 18.3.5. Analysis of Amount Invested by Year and Type of Funding
- 18.3.6. Analysis of Amount Invested by Type of Device
- 18.3.7. Analysis by Target Disease Indication
- 18.3.8. Most Active Players: Analysis by Number of Funding Instances
- 18.3.9. Most Active Players: Analysis by Amount Invested
- 18.3.10. Leading Investors: Analysis by Number of Funding Instances
- 18.3.11. Analysis by Geography

19. SWOT ANALYSIS

19.1. Chapter Overview
19.2. SWOT Analysis
- 19.2.1. Strengths
- 19.2.2. Weaknesses
- 19.2.3. Opportunities
- 19.2.4. Threats
19.3. Wearable Injectors: Future Growth Opportunities
- 19.3.1. Rising Focus on Self-Administration of Drugs
- 19.3.2. Possibility of Integration with Mobile Applications
- 19.3.3. Potential Life Cycle Management Tool
- 19.3.4. Potential Usability for Multiple Therapeutic Areas

20. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN

20.1. Chapter Overview
20.2. Device Development Supply Chain
20.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development
20.4. List of CMOs
- 20.4.1. Geographical Distribution of CMOs
20.5. Medical Devices Design and Development Service Providers

21. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

21.1. Chapter Overview
21.2. General Regulatory and Reimbursement Guidelines for Medical Devices
21.3. Regulatory and Reimbursement Landscape in North America
- 21.3.1. The US Scenario
  - 21.3.1.1. Regulatory Authority
  - 21.3.1.2. Review / Approval Process
  - 21.3.1.3. Reimbursement Landscape
    - 21.3.1.3.1. Payer Mix
    - 21.3.1.3.2. Reimbursement Process
- 21.3.2. The Canadian Scenario
  - 21.3.2.1. Regulatory Authority
  - 21.3.2.2. Review / Approval Process
  - 21.3.2.3. Reimbursement Landscape
    - 21.3.2.3.1. Payer Mix
    - 21.3.2.3.2. Reimbursement Process
- 21.3.3. The Mexican Scenario
  - 21.3.3.1. Regulatory Authority
  - 21.3.3.2. Review / Approval Process
  - 21.3.3.3. Reimbursement Landscape
    - 21.3.3.3.1. Payer Mix
21.4. Regulatory and Reimbursement Landscape in Europe
- 21.4.1. Overall Scenario
  - 21.4.1.1. Overall Regulatory Authority
  - 21.4.1.2. Overall Review / Approval Process
- 21.4.2. The UK Scenario
  - 21.4.2.1. Regulatory Authority
  - 21.4.2.2. Review / Approval Process
  - 21.4.2.3. Reimbursement Landscape
    - 21.4.2.3.1. Payer Mix
    - 21.4.2.3.2. Reimbursement Process
- 21.4.3. The French Scenario
  - 21.4.3.1. Regulatory Authority
  - 21.4.3.2. Review / Approval Process
  - 21.4.3.3. Reimbursement Landscape
    - 21.4.3.3.1. Payer Mix
    - 21.4.3.3.2. Reimbursement Process
- 21.4.4. The German Scenario
  - 21.4.4.1. Regulatory Authority
  - 21.4.4.2. Review / Approval Process
  - 21.4.4.3. Reimbursement Landscape
    - 21.4.4.3.1. Payer Mix
    - 21.4.4.3.2. Reimbursement Process
- 21.4.5. The Italian Scenario
  - 21.4.5.1. Regulatory Authority
  - 21.4.5.2. Review / Approval Process
  - 21.4.5.3. Reimbursement Landscape
    - 21.4.5.3.1. Payer Mix
    - 21.4.5.3.2. Reimbursement Process
- 21.4.6. The Spanish Scenario
  - 21.4.6.1. Regulatory Authority
  - 21.4.6.2. Review / Approval Process
  - 21.4.6.3. Reimbursement Landscape
    - 21.4.6.3.1. Payer Mix
    - 21.4.6.3.2. Reimbursement Process
21.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
- 21.5.1. The Australian Scenario
  - 21.5.1.1. Regulatory Authority
  - 21.5.1.2. Review / Approval Process
  - 21.5.1.3. Reimbursement Landscape
    - 21.5.1.3.1. Payer Mix
    - 21.5.1.3.2. Reimbursement Process
- 21.5.2. The Brazilian Scenario
  - 21.5.2.1. Regulatory Authority
  - 21.5.2.2. Review / Approval Process
  - 21.5.2.3. Reimbursement Landscape
    - 21.5.2.3.1. Payer Mix
    - 21.5.2.3.2. Reimbursement Process
- 21.5.3. The Chinese Scenario
  - 21.5.3.1. Regulatory Authority
  - 21.5.3.2. Review / Approval Process
  - 21.5.3.3. Reimbursement Landscape
    - 21.5.3.3.1. Payer Mix
    - 21.5.3.3.2. Reimbursement Process

22. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

22.1. Chapter Overview
22.2. Market Drivers
22.3. Market Restraints
22.4. Market Opportunities
22.5. Market Challenges
22.6. Conclusion

23. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 23.3.1. Scenario Analysis
  - 23.3.1.1. Conservative Scenario
  - 23.3.1.2. Optimistic Scenario
23.4. Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 23.4.1. Scenario Analysis
  - 23.4.1.1. Conservative Scenario
  - 23.4.1.2. Optimistic Scenario
23.5. Key Market Segmentations

24. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY TYPE OF DEVICE

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
- 24.3.1. Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 24.3.2. Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
24.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
- 24.4.1. Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 24.4.2. Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
24.5. Data Triangulation and Validation

25. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY USABILITY

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
- 25.3.1. Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 25.3.2. Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
25.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
- 25.4.1. Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 25.4.2. Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
25.5. Data Triangulation and Validation

26. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY THERAPEUTIC AREA

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
- 26.3.1. Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 26.3.2. Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 26.3.3. Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 26.3.4. Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 26.3.5. Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
26.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
- 26.4.1. Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 26.4.2. Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 26.4.3. Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 26.4.4. Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 26.4.5. Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
26.5. Data Triangulation and Validation

27. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY GEOGRAPHICAL REGIONS

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
- 27.3.1. Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 27.3.2. Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 27.3.3. Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 27.3.4. Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 27.3.5. Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
27.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
- 27.4.1. Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 27.4.2. Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 27.4.3. Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 27.4.4. Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 27.4.5. Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
27.5. Market Dynamics Assessment
- 27.5.1. Penetration Growth (P-G) Matrix
- 27.5.2. Market Movement Analysis
27.6. Data Triangulation and Validation

28. WEARABLE INJECTORS MARKET FOR INSULIN

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 28.3.1. Scenario Analysis
  - 28.3.1.1. Conservative Scenario
  - 28.3.1.2. Optimistic Scenario
28.4. Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 28.4.1. Scenario Analysis
  - 28.4.1.1. Conservative Scenario
  - 28.4.1.2. Optimistic Scenario
28.5. Key Market Segmentations

29. WEARABLE INJECTORS MARKET FOR INSULIN, BY TYPE OF DEVICE

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
- 29.3.1. Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 29.3.2. Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
29.4. Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
- 29.4.1. Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 29.4.2. Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
29.5. Data Triangulation and Validation

30. WEARABLE INJECTORS MARKET FOR INSULIN, BY DEGREE OF AUTOMATION

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
- 30.3.1. Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 30.3.2. Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
30.4. Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
- 30.4.1. Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 30.4.2. Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
30.5. Data Triangulation and Validation

31. WEARABLE INJECTORS MARKET FOR INSULIN, BY GEOGRAPHICAL REGIONS

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
- 31.3.1. Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.1.1. Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.1.2. Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 31.3.2. Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.1. Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.2. Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.3. Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.4. Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.5. Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.6. Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 31.3.3. Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.1. Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.2. Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.3. Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.4. Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.5. Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 31.3.4. Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.4.1. Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.4.2. Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.4.3. Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 31.3.5. Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.5.1. Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.5.2. Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.5.3. Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.4. Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
- 31.4.1. Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.1.1. Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.1.2. Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 31.4.2. Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.1. Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.2. Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.3. Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.4. Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.5. Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.6. Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 31.4.3. Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.1. Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.2. Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.3. Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.4. Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.5. Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 31.4.4. Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.4.1. Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.4.2. Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.4.3. Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 31.4.5. Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.5.1. Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.5.2. Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.5.3. Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.5. Market Dynamics Assessment
- 31.5.1. Penetration Growth (P-G) Matrix
- 31.5.2. Market Movement Analysis
31.6. Data Triangulation and Validation

32. CONCLUDING INSIGHTS

33. EXECUTIVE INSIGHTS

34. APPENDIX I: TABULATED DATA

35. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

简介目录图表

List of Tables

Table 7.1 Wearable Injectors for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 7.2 Wearable Injectors for Non-Insulin Drugs: Information on Type of Dose, Type of Drug Container and Mode of Drug Filling
Table 7.3 Wearable Injectors for Non-Insulin Drugs: Information on Container Volume, Route of Administration and Mode of Injection
Table 7.4 Wearable Injectors for Non-Insulin Drugs: Information on Mechanism of Action / Driving Force and Type of Technology
Table 7.5 Wearable Injectors for Non-Insulin Drugs: Information on Availability of Connectivity Feature and Type of Compatible Drug
Table 7.6 Wearable Injectors for Non-Insulin Drugs: Information on Compatibility with High Viscosity Drugs and Therapeutic Area
Table 7.7 Wearable Injectors for Non-Insulin Drugs: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 8.1 Drug Device Combinations for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 8.2 Drug Device Combinations for Non-Insulin Drugs: Information on Type of Dose, Mode of Drug Filling, Type of Drug Container and Container Volume
Table 8.3 Drug Device Combinations for Non-Insulin Drugs: Information on Route of Administration, Mode of Injection and Type of Compatible Drug
Table 8.4 Drug Device Combinations for Non-Insulin Drugs: Information on Drug Delivery Technology, Mechanism of Action / Driving Force and Therapeutic Area
Table 8.5 Drug Device Combinations for Non-Insulin Drugs: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 9.1 Wearable Injectors for Insulin: Information on Status of Development, Type of Device and Type of Insulin Delivery
Table 9.2 Wearable Injectors for Insulin: Information on Type of Automated Insulin Delivery, Type of Connectivity Feature and Type of Feedback Mechanism
Table 9.3 Wearable Injectors for Insulin: Information on Waterproofing Capability, Usability and Period of Use
Table 9.4 Wearable Injectors for Insulin: Information on Type of Advanced Feature, Type of Drug Container and Mode of Drug Filling
Table 9.5 Wearable Injectors for Insulin: Information on Type of Dose, Type of Diabetes and Availability of Connectivity Feature
Table 9.6 Wearable Injectors for Insulin: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 11.1 Wearable Injector Developers: List of Companies Profiled
Table 11.2 CCBio: Company Overview
Table 11.3 CCBio: Device Portfolio
Table 11.4 CCBio: Recent Developments and Future Outlook
Table 11.5 E3D Elcam Drug Delivery Device: Company Overview
Table 11.6 E3D Elcam Drug Delivery Device: Device Portfolio
Table 11.7 E3D Elcam Drug Delivery Devices: Recent Developments and Future Outlook
Table 11.8 Enable Injections: Company Overview
Table 11.9 Enable Injections: Device Portfolio
Table 11.10 Enable Injections: Recent Developments and Future Outlook
Table 11.11 Gerresheimer: Company Overview
Table 11.12 Gerresheimer: Device Portfolio
Table 11.13 Gerresheimer: Recent Developments and Future Outlook
Table 11.14 Sonceboz: Company Overview
Table 11.15 Sonceboz: Device Portfolio
Table 11.16 Sonceboz: Recent Developments and Future Outlook
Table 11.17 Weibel CDS: Company Overview
Table 11.18 Weibel CDS: Device Portfolio
Table 11.19 Weibel CDS: Developments and Future Outlook
Table 11.20 West Pharmaceuticals: Company Overview
Table 11.21 West Pharmaceuticals: Device Portfolio
Table 11.22 West Pharmaceuticals: Developments and Future Outlook
Table 11.23 CeQur: Company Overview
Table 11.24 CeQur: Device Portfolio
Table 11.25 CeQur: Developments and Future Outlook
Table 11.26 Eli Lilly: Company Overview
Table 11.27 Eli Lilly: Device Portfolio
Table 11.28 Eli Lilly: Developments and Future Outlook
Table 11.29 Insulet: Company Overview
Table 11.30 Insulet: Device Portfolio
Table 11.31 Insulet: Developments and Future Outlook
Table 11.32 Medtronic: Company Overview
Table 11.33 Medtronic: Device Portfolio
Table 11.34 Medtronic: Developments and Future Outlook
Table 11.35 Medtrum Technologies: Company Overview
Table 11.36 Medtrum Technologies: Device Portfolio
Table 11.37 Medtrum Technologies: Developments and Future Outlook
Table 11.38 Roche: Company Overview
Table 11.39 Roche: Device Portfolio
Table 11.40 Roche: Developments and Future Outlook
Table 11.41 SOOIL Development: Company Overview
Table 11.42 SOOIL Development: Device Portfolio
Table 11.43 SOOIL Development: Developments and Future Outlook
Table 12.1 Drug Device Combination: 3 mL Micropump (Furosemide)
Table 12.2 Drug Device Combination: 3M hMTS (Adalimumab)
Table 12.3 Drug Device Combination: D-mine Pump (Apomorphine)
Table 12.4 Drug Device Combination: On-body Infusor (Furosemide)
Table 12.5 Drug Device Combination: Herceptin SC Injector (Herceptin)
Table 12.6 Drug Device Combination: ND0712H Belt Pump (Levodopa / Carbidopa)
Table 12.7 Drug Device Combination: ND0712L belt pump (Levodopa / Carbidopa)
Table 12.8 Drug Device Combination: ND0712L next generation patch pump (Levodopa / Carbidopa)
Table 12.9 Drug Device Combination: ND0801 (Apomorphine)
Table 12.10 Drug Device Combination: ND0901 (Levodopa / Carbidopa)
Table 12.11 Drug Device Combination: Neulasta Onpro On-Body Injector (Neulasta)
Table 12.12 Drug Device Combination: Pushtronex System (Repatha)
Table 12.13 Drug Device Combination: SMT-201 (Ketorolac)
Table 12.14 Drug Device Combination: SMT-301 (Bupivacaine)
Table 12.15 Drug Device Combination: The LUTREPULSE System (Lutrepulse)
Table 12.16 Drug Device Combination: Trevyent (Treprostinil)
Table 12.17 Drug Device Combination: Ultomris (Ravulizumab)
Table 13.1 Wearable Injectors: List of Partnerships and Collaborations, 2018-2021
Table 14.1 Wearable Injectors: List of Key Acquisitions, 2000-2023
Table 14.2 Non-Insulin Drug Delivery Devices: Likelihood of Players for Acquisition
Table 14.3 Insulin Delivery Devices: Likelihood of Players for Acquisition
Table 15.1 Patent Analysis: Prominent CPC Symbols
Table 15.2 Patent Analysis: List of Top CPC Symbols
Table 15.3 Patent Analysis: Most Popular CPC Symbols
Table 15.4 Patent Analysis: Summary of Benchmarking Analysis
Table 15.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 15.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 16.1 Marketed Drugs: Most Likely Candidates for Delivery via Wearable Injectors
Table 16.2 Marketed Drugs: Likely Candidates for Delivery via Wearable Injectors
Table 16.3 Marketed Drugs: Less Likely Candidates for Delivery via Wearable Injectors
Table 16.4 Marketed Drugs: Least Likely Candidates for Delivery via Wearable Injectors
Table 16.5 Clinical Stage Drugs: Most Likely Candidates for Delivery via Wearable Injectors
Table 16.6 Clinical Stage Drugs: Likely Candidates for Delivery via Wearable Injectors
Table 16.7 Clinical Stage Drugs: Less Likely Candidates for Delivery via Wearable Injectors
Table 16.8 Clinical Stage Drugs: Least Likely Candidates for Delivery via Wearable Injectors
Table 18.1 List of Funding Instances: Information on Company, Year of Funding, Type, Amount Invested and Investors
Table 20.1 List of Contract Manufacturing Organizations
Table 20.2 List of Medical Device Product Design and Development Companies
Table 21.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 21.2 Device Classification: US
Table 21.3 Device Classification: Canada
Table 21.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 21.5 Device Classification: Mexico
Table 21.6 Device Classification: Europe
Table 21.7 List of CE Directives in Europe
Table 21.8 Conformity Assessment Modules in Europe
Table 21.9 Device Classification: Australia
Table 21.10 Medical Devices Reimbursement and Pricing Approval Process: Australia
Table 21.11 Device Classification: Brazil
Table 21.12 Device Classification: China
Table 21.13 Device Classification: India
Table 21.14 Device Classification: Japan
Table 21.15 Medical Devices Reimbursement Categories
Table 21.16 Device Classification: Medsafe
Table 21.17 Device Classification: Singapore
Table 21.18 Device Classification: South Korea
Table 21.19 Device Classification: South Africa
Table 21.20 Device Classification: Thailand
Table 21.21 Medical Devices Regulatory Landscape Summary
Table 21.22 Medical Devices Reimbursement Landscape Summary
Table 25.1 Company Snapshot: Company A
Table 25.2 Company Snapshot: Company B
Table 25.3 Company Snapshot: Company C
Table 25.4 Company Snapshot: Company D
Table 25.5 Company Snapshot: Company E
Table 25.6 Company Snapshot: Company F
Table 25.7 Company Snapshot: Company G
Table 25.8 Company Snapshot: Company H
Table 25.9 Company Snapshot: Company I
Table 25.10 Company Snapshot: Company J
Table 34.1 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 34.2 Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Table 34.3 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.4 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Table 34.5 Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 34.6 Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Table 34.7 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Table 34.8 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 34.9 Wearable Injectors for Non-Insulin Drugs: Distribution by Dose of Drug
Table 34.10 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Table 34.11 Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 34.12 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 34.13 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.14 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Year of Establishment
Table 34.15 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Company Size
Table 34.16 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.17 Leading Players: Distribution by Number of Wearable Injectors Developed for Non-Insulin
Table 34.18 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Table 34.19 Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Table 34.20 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Table 34.21 Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Table 34.22 Drug Device Combinations for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Table 34.23 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Table 34.24 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Table 34.25 Drug Device Combinations for Non-Insulin Drugs: Distribution by Dose of Drug
Table 34.26 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Table 34.27 Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 34.28 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 34.29 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.30 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Year of Establishment
Table 34.31 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Company Size
Table 34.32 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.33 Device Developers: Distribution by Number of Drug Device Combination Developed
Table 34.34 Wearable Injectors for Insulin: Distribution by Type of Device
Table 34.35 Wearable Injectors for Insulin: Distribution by Status of Development
Table 34.36 Wearable Injectors for Insulin: Distribution by Type of Insulin Delivery
Table 34.37 Wearable Injectors for Insulin: Distribution by Type of Automated Insulin Delivery
Table 34.38 Wearable Injectors for Insulin: Distribution by Type of Connectivity Feature
Table 34.39 Wearable Injectors for Insulin: Distribution by Waterproof Capability
Table 34.40 Wearable Injectors for Insulin: Distribution by Usability
Table 34.41 Wearable Injectors for Insulin: Distribution by Period of Use
Table 34.42 Wearable Injectors for Insulin: Distribution by Type of Advanced Feature
Table 34.43 Wearable Injectors for Insulin: Distribution by Type of Drug Container
Table 34.44 Wearable Injectors for Insulin: Distribution by Mode of Drug Filling
Table 34.45 Wearable Injectors for Insulin: Distribution by Type of Dose
Table 34.46 Wearable Injectors for Insulin: Distribution by Type of Diabetes
Table 34.47 Wearable Injectors for Insulin: Distribution by Availability of Connectivity Feature
Table 34.48 Wearable Injectors for Insulin Drug Developers: Distribution by Year of Establishment
Table 34.49 Wearable Injectors for Insulin Drug Developers: Distribution by Company Size
Table 34.50 Wearable Injectors for Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.51 Leading Players: Distribution by Number of Wearable Injectors for Insulin
Table 34.52 Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
Table 34.53 Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
Table 34.54 Product Competitiveness Analysis: Wearable Injectors for Insulin
Table 34.55 Gerresheimer: Annual Revenues, FY 2022 Onwards (EUR Million)
Table 34.56 West Pharmaceuticals: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.57 Eli Lilly: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.58 Insulet: Annual Revenues, FY 2022 Onwards (USD Million)
Table 34.59 Medtronic: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.60 Roche: Annual Revenues, FY 2022 Onwards (CHF Billion)
Table 34.61 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Table 34.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 34.63 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2015
Table 34.64 Partnerships and Collaborations: Distribution by Partner
Table 34.65 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 34.66 Partnerships and Collaborations: Distribution by Type of Device
Table 34.67 Most Active Players: Distribution by Number of Partnerships
Table 34.68 Most Active Players: Distribution by Type of Partnership
Table 34.69 Partnerships and Collaborations: Local and International Agreements
Table 34.70 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 34.71 Patent Analysis: Distribution by Type of Patent
Table 34.72 Patent Analysis: Distribution by Patent Publication Year
Table 34.73 Patent Analysis: Distribution by Patent Application Year
Table 34.74 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year
Table 34.75 Patent Analysis: Distribution by Jurisdiction
Table 34.76 Patent Analysis: Distribution by Type of Applicant
Table 34.77 Leading Industry Players: Distribution by Number of Patents
Table 34.78 Leading Non-Industry Players: Distribution by Number of Patents
Table 34.79 Leading Individual Assignees: Distribution by Number of Patents
Table 34.80 Patent Analysis: Distribution by Patent Age
Table 34.81 Wearable Injectors: Patent Valuation
Table 34.82 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 34.83 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 34.84 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 34.85 Clinical Trial Analysis: Distribution by Trial Phase
Table 34.86 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 34.87 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Table 34.88 Clinical Trial Analysis: Distribution by Study Design
Table 34.89 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 34.90 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 34.91 Most Active Players: Distribution by Number of Registered Trials
Table 34.92 Most Popular Wearable Injectors: Distribution by Number of Registered Trials
Table 34.93 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 34.94 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Table 34.95 Funding and Investment Analysis: Distribution of Year of Funding, Since 2014
Table 34.96 Funding and Investment Analysis: Distribution of Amount Invested by Year, Since 2014 (USD Million)
Table 34.97 Funding and Investment Analysis: Distribution by Type of Funding
Table 34.98 Funding and Investment Analysis: Distribution by Type of Device
Table 34.99 Funding and Investment Analysis: Year-wise Distribution by Type of Funding and Amount Raised (USD Million)
Table 34.100 Funding and Investment Analysis: Distribution by Target Disease Indication
Table 34.101 Most Active Players: Distribution by Number of Funding Instances
Table 34.102 Most Active Players: Distribution by Amount Invested
Table 34.103 Leading Investors: Distribution by Number of Funding Instances
Table 34.104 Funding and Investments: Distribution by Geography
Table 34.105 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.106 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.107 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
Table 34.108 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.109 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.110 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
Table 34.111 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.112 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.113 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
Table 34.114 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.115 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.116 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
Table 34.117 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.118 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.119 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
Table 34.120 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.121 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.122 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.123 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.124 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.125 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
Table 34.126 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.127 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.128 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.129 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.130 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.131 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
Table 34.132 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.133 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.134 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.135 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.136 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.137 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
Table 34.138 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.139 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.140 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.141 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.142 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.143 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.144 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.145 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
Table 34.146 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.147 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.148 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
Table 34.149 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.150 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.151 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
Table 34.152 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.153 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.154 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
Table 34.155 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.156 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.157 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
Table 34.158 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.159 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.160 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.161 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.162 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.163 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.164 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.165 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.166 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.167 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.168 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.169 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.170 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.171 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.172 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.173 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.174 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.175 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.176 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.177 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.178 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.179 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.180 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.181 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.182 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
Table 34.183 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.184 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.185 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.186 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.187 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.188 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.189 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.190 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.191 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.192 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.193 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.194 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.195 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.196 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.197 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.198 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.199 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.200 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.201 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.202 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.203 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.204 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.205 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.206 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Drug Delivery Systems
Figure 6.2 Evolution of Healthcare Safety Legislations
Figure 6.3 Wearable Injectors Market: Key Driving Factors
Figure 6.4 Types of Self-Injection Devices
Figure 7.1 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 7.2 Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Figure 7.3 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 7.4 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Figure 7.5 Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 7.6 Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Figure 7.7 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Figure 7.8 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 7.9 Wearable Injectors for Non-Insulin Drugs: Distribution by Dose of Drug
Figure 7.10 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 7.11 Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 7.12 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 7.13 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 7.14 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Year of Establishment
Figure 7.15 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Company Size
Figure 7.16 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Figure 7.17 Leading Players: Distribution by Number of Wearable Injectors Developed for Non-Insulin
Figure 8.1 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Figure 8.2 Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Figure 8.3 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Figure 8.4 Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Figure 8.5 Drug Device Combinations for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Figure 8.6 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Figure 8.7 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Figure 8.8 Drug Device Combinations for Non-Insulin Drugs: Distribution by Dose of Drug
Figure 8.9 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 8.10 Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 8.11 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 8.12 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 8.13 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Year of Establishment
Figure 8.14 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Company Size
Figure 8.15 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Figure 8.16 Device Developers: Distribution by Number of Drug Device Combination Developed
Figure 9.1 Wearable Injectors for Insulin: Distribution by Type of Device
Figure 9.2 Wearable Injectors for Insulin: Distribution by Status of Development
Figure 9.3 Wearable Injectors for Insulin: Distribution by Type of Insulin Delivery
Figure 9.4 Wearable Injectors for Insulin: Distribution by Type of Automated Insulin Delivery
Figure 9.5 Wearable Injectors for Insulin: Distribution by Type of Connectivity Feature
Figure 9.6 Wearable Injectors for Insulin: Distribution by Waterproof Capability
Figure 9.7 Wearable Injectors for Insulin: Distribution by Usability
Figure 9.8 Wearable Injectors for Insulin: Distribution by Period of Use
Figure 9.9 Wearable Injectors for Insulin: Distribution by Type of Advanced Feature
Figure 9.10 Wearable Injectors for Insulin: Distribution by Type of Drug Container
Figure 9.11 Wearable Injectors for Insulin: Distribution by Mode of Drug Filling
Figure 9.12 Wearable Injectors for Insulin: Distribution by Type of Dose
Figure 9.13 Wearable Injectors for Insulin: Distribution by Type of Diabetes
Figure 9.14 Wearable Injectors for Insulin: Distribution by Availability of Connectivity Feature
Figure 9.15 Wearable Injectors for Insulin Drug Developers: Distribution by Year of Establishment
Figure 9.16 Wearable Injectors for Insulin Drug Developers: Distribution by Company Size
Figure 9.17 Wearable Injectors for Insulin Drug Developers: Distribution by Location of Headquarters
Figure 9.18 Leading Players: Distribution by Number of Wearable Injectors for Insulin
Figure 10.1 Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
Figure 10.2 Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
Figure 10.3 Product Competitiveness Analysis: Wearable Injectors for Insulin
Figure 11.1 Gerresheimer: Annual Revenues, FY 2022 Onwards (EUR Million)
Figure 11.2 West Pharmaceuticals: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.3 Eli Lilly: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.4 Insulet: Annual Revenues, FY 2022 Onwards (USD Million)
Figure 11.5 Medtronic: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.6 Roche: Annual Revenues, FY 2022 Onwards (CHF Billion)
Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2015
Figure 13.4 Partnerships and Collaborations: Distribution by Partner
Figure 13.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 13.6 Partnerships and Collaborations: Distribution by Type of Device
Figure 13.7 Most Active Players: Distribution by Number of Partnerships
Figure 13.8 Most Active Players: Distribution by Type of Partnership
Figure 13.9 Partnerships and Collaborations: Local and International Agreements
Figure 13.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 15.1 Patent Analysis: Distribution by Type of Patent
Figure 15.2 Patent Analysis: Distribution by Patent Publication Year
Figure 15.3 Patent Analysis: Distribution by Patent Application Year
Figure 15.4 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year
Figure 15.5 Patent Analysis: Distribution by Jurisdiction
Figure 15.6 Patent Analysis: Distribution by Type of Applicant
Figure 15.7 Patent Analysis: Distribution by CPC Symbols
Figure 15.8 Leading Industry Players: Distribution by Number of Patents
Figure 15.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 15.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 15.11 Patent Benchmarking: Distribution by Patent Characteristics (CPC Symbols)
Figure 15.12 Patent Analysis: Distribution by Patent Age
Figure 15.13 Wearable Injectors: Patent Valuation
Figure 17.1 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 17.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 17.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 17.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 17.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 17.6 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Figure 17.7 Clinical Trial Analysis: Distribution by Study Design
Figure 17.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 17.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 17.10 Most Active Players: Distribution by Number of Registered Trials
Figure 17.11 Most Popular Wearable Injectors: Distribution by Number of Registered Trials
Figure 17.12 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 17.13 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Figure 18.1 Funding and Investment Analysis: Distribution of Year of Funding, Since 2014
Figure 18.2 Funding and Investment Analysis: Distribution of Amount Invested by Year, Since 2014 (USD Million)
Figure 18.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 18.4 Funding and Investment Analysis: Distribution by Type of Device
Figure 18.5 Funding and Investment Analysis: Year-wise Distribution by Type of Funding and Amount Raised (USD Million)
Figure 18.6 Funding and Investment Analysis: Distribution by Target Disease Indication
Figure 18.7 Most Active Players: Distribution by Number of Funding Instances
Figure 18.8 Most Active Players: Distribution by Amount Invested
Figure 18.9 Leading Investors: Distribution by Number of Funding Instances
Figure 18.10 Funding and Investments: Distribution by Geography
Figure 19.1 SWOT Factors: Harvey Ball Analysis
Figure 20.1 CMOs: Distribution by Geography
Figure 21.1 Key Regulatory Authorities for Medical Devices
Figure 21.2 Medical Devices Review / Approval Process in the US
Figure 21.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 21.4 Medical Devices National Coverage Determination Process: US
Figure 21.5 Medical Devices Review / Approval Process in Canada
Figure 21.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 21.7 Medical Devices Review / Approval Process in Mexico
Figure 21.8 Regulatory Bodies in EU5 Countries
Figure 21.9 Steps involved in CE Marking Process
Figure 21.10 Medical Devices Review / Approval Process in Europe
Figure 21.11 Medical Devices Review / Approval Process in the UK
Figure 21.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 21.13 Medical Devices Reimbursement Process: UK
Figure 21.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 21.15 Medical Devices Reimbursement Process: France
Figure 21.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 21.17 Medical Devices Reimbursement Process for In-Patient Setting: Germany
Figure 21.18 Medical Devices Reimbursement Process for Out-Patient Care: Germany
Figure 21.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 21.20 Medical Devices Reimbursement Process: Italy
Figure 21.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 21.22 Medical Devices Reimbursement Process: Spain
Figure 21.23 Medical Devices Review / Approval Process in Australia
Figure 21.24 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Figure 21.25 Medical Devices Review / Approval Process in Brazil
Figure 21.26 Medical Devices Reimbursement Process: Brazil
Figure 21.27 Medical Devices Review / Approval Process in China
Figure 21.28 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Figure 21.29 Medical Devices Reimbursement Process: Shanghai
Figure 21.30 Medical Devices Review / Approval Process in India
Figure 21.31 Healthcare Insurance Coverage in Israel: Distribution by Type of Coverage
Figure 21.32 Medical Devices Review / Approval Process in Japan
Figure 21.33 Medical Devices Reimbursement Process: Japan
Figure 21.34 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Figure 21.35 New Medical Devices Reimbursement Process: Japan
Figure 21.36 Medical Devices Review / Approval Process in New Zealand
Figure 21.37 Healthcare Insurance Coverage in New Zealand: Distribution by Type of Coverage
Figure 21.38 Medical Devices Review / Approval Process in Singapore
Figure 21.39 Medical Devices Review / Approval Process in South Korea
Figure 21.40 Healthcare Insurance Coverage in South Korea: Distribution by Type of Coverage
Figure 21.41 Medical Devices Review / Approval Process in South Africa
Figure 21.42 Medical Devices Review / Approval Process in Taiwan
Figure 21.43 Healthcare Insurance Coverage in Taiwan: Distribution by Type of Coverage
Figure 21.44 Medical Devices Review / Approval Process in Thailand
Figure 21.45 Heat Map Analysis: Comparison of Regional Regulatory Guidelines for Medical Devices
Figure 21.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
Figure 23.1 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 23.2 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 24.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
Figure 24.2 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 24.3 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 24.4 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
Figure 24.5 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 24.6 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 25.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
Figure 25.2 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 25.3 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 25.4 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
Figure 25.5 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 25.6 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
Figure 26.2 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.3 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.4 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.5 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.6 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.7 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
Figure 26.8 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.9 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.10 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.11 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.12 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
Figure 27.2 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.3 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.4 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.5 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.6 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.7 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
Figure 27.8 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.9 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.10 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.11 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.12 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.13 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 27.14 Market Movement Analysis: Geographical Regions
Figure 28.1 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 28.2 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 29.1 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
Figure 29.2 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 29.3 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 29.4 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
Figure 29.5 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 29.6 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 30.1 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
Figure 30.2 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 30.3 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 30.4 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
Figure 30.5 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 30.6 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.1 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
Figure 31.2 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.3 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.4 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.5 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.6 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.7 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.8 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.9 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.10 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.11 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.12 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.13 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.14 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.15 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.16 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.17 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.18 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.19 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.20 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.21 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.22 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.23 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.24 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.25 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.26 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
Figure 31.27 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.28 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.29 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.30 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.31 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.32 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.33 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.34 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.35 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.36 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.37 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.38 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.39 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.40 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.41 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.42 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.43 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.44 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.45 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.46 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.47 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.48 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.49 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.50 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.51 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 31.52 Market Movement Analysis: Geographical Regions
Figure 32.1 Concluding Remarks: Market Landscape of Wearable Injectors for Non-Insulin
Figure 32.2 Concluding Remarks: Market Landscape of Drug Device Combinations
Figure 32.3 Concluding Remarks: Market Landscape of Wearable Injectors for Insulin
Figure 32.4 Concluding Remarks: Partnerships and Collaborations
Figure 32.5 Concluding Remarks: Key Acquisition Targets
Figure 32.6 Concluding Remarks: Patent Analysis
Figure 32.7 Concluding Remarks: Likely Drug Candidates
Figure 32.8 Concluding Remarks: Clinical Trial Analysis
Figure 32.9 Concluding Remarks: Funding and Investment Analysis
Figure 32.10 Concluding Remarks: Market Sizing and Opportunity Analysis for Wearable Injectors for Non-Insulin
Figure 32.11 Concluding Remarks: Market Sizing and Opportunity Analysis for Wearable Injectors for Insulin

02-2729-4219

+886-2-2729-4219

License/价格

穿戴式注射器市场（第8版）：依装置类型、自动化程度、用途、治疗领域和地区划分 - 趋势及至2035年的预测

Wearable Injectors Market (8th Edition): Distribution by Type of Device, Degree of Automation, Usability, Therapeutic Area, and Geographical Regions - Trends and Forecast Till 2035

穿戴式注射器市场 - 概述

穿戴式注射器市场的主要参与者

目录

第1章 引言

第2章 研究方法

第3章 市场动态

第4章 宏观经济指标

第5章 执行摘要

第6章 引言

第7章 非胰岛素药物穿戴注射器：市场

第8章 非胰岛素药物-器材组合：市场概况

第9章 胰岛素药物穿戴式注射器：市场概况

第10章 产品竞争分析

第11章 穿戴式注射器开发商：公司简介

第12章 药物-器械组合：器械简介

第13章 合作与伙伴关係

第14章 重点收购目标

第15章 专利分析

第16章 穿戴式注射器：有前景的候选药物

第17章 临床试验分析

第18章 资金与投资分析

第19章 SWOT分析

第20章 案例研究：合约製造组织在医疗器材开发供应链中的作用

第21章 医疗器材监管与偿付现况

第22章 市场影响分析：驱动因素、限制因素、机会与挑战

第23章 非胰岛素药物穿戴式注射器

第24章 非胰岛素药物穿戴式注射器（依装置类型划分）

第25章 非胰岛素药物穿戴式注射器市场（依用途划分）

第26章 非胰岛素药物穿戴式注射器市场（依治疗领域划分）

第27章 非胰岛素药物穿戴式注射器市场（依地区划分）

第28章 胰岛素药物穿戴式注射器市场

第29章 胰岛素药物穿戴式注射器市场（依装置类型划分）

第30章 胰岛素药物穿戴式注射器市场（依自动化程度划分）

第31章 胰岛素药物穿戴式注射器市场（依地区划分）

第32章 结论

第33章 高层洞察

第34章 附录1：表格资料

第35章 附录2：公司与组织列表

Wearable Injectors Market: Overview

Primary Research Overview

Example Players in Wearable Injectors Market

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. WEARABLE INJECTORS FOR NON-INSULIN DRUGS: MARKET LANDSCAPE

8. DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: MARKET LANDSCAPE

9. WEARABLE INJECTORS FOR INSULIN: MARKET LANDSCAPE

10. PRODUCT COMPETITIVENESS ANALYSIS

11. WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES

12. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES

13. PARTNERSHIPS AND COLLABORATIONS

14. KEY ACQUISITION TARGETS

15. PATENT ANALYSIS

16. WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

17. CLINICAL TRIAL ANALYSIS

18. FUNDING AND INVESTMENT ANALYSIS

19. SWOT ANALYSIS

20. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN

21. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

22. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

23. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS

24. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY TYPE OF DEVICE

25. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY USABILITY

26. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY THERAPEUTIC AREA

27. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY GEOGRAPHICAL REGIONS

28. WEARABLE INJECTORS MARKET FOR INSULIN

29. WEARABLE INJECTORS MARKET FOR INSULIN, BY TYPE OF DEVICE

30. WEARABLE INJECTORS MARKET FOR INSULIN, BY DEGREE OF AUTOMATION

31. WEARABLE INJECTORS MARKET FOR INSULIN, BY GEOGRAPHICAL REGIONS

32. CONCLUDING INSIGHTS

33. EXECUTIVE INSIGHTS

34. APPENDIX I: TABULATED DATA

35. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

第1章引言

第2章研究方法

第3章市场动态

第4章宏观经济指标

第5章执行摘要

第6章引言

第7章非胰岛素药物穿戴注射器：市场

第8章非胰岛素药物-器材组合：市场概况

第9章胰岛素药物穿戴式注射器：市场概况

第10章产品竞争分析

第11章穿戴式注射器开发商：公司简介

第12章药物-器械组合：器械简介

第13章合作与伙伴关係

第14章重点收购目标

第15章专利分析

第16章穿戴式注射器：有前景的候选药物

第17章临床试验分析

第18章资金与投资分析

第20章案例研究：合约製造组织在医疗器材开发供应链中的作用

第21章医疗器材监管与偿付现况

第22章市场影响分析：驱动因素、限制因素、机会与挑战

第23章非胰岛素药物穿戴式注射器

第24章非胰岛素药物穿戴式注射器（依装置类型划分）

第25章非胰岛素药物穿戴式注射器市场（依用途划分）

第26章非胰岛素药物穿戴式注射器市场（依治疗领域划分）

第27章非胰岛素药物穿戴式注射器市场（依地区划分）

第28章胰岛素药物穿戴式注射器市场

第29章胰岛素药物穿戴式注射器市场（依装置类型划分）

第30章胰岛素药物穿戴式注射器市场（依自动化程度划分）

第31章胰岛素药物穿戴式注射器市场（依地区划分）

第32章结论

第33章高层洞察

第34章附录1：表格资料

第35章附录2：公司与组织列表